Use-result Surveillance for PADCEV Injection 20 mg and 30 mg (Enfortumab Vedotin) in South Korea

What this Trial Is About

Researchers are studying adults in South Korea who have locally advanced or metastatic urothelial cancer, a type of cancer in the bladder lining that has spread to other parts of the body. The study focuses on people who have been prescribed PADCEV Injection (enfortumab vedotin) as part of their cancer treatment. The main goal is to collect information about treatment outcomes and any medical problems that arise during care. Participants receive PADCEV Injection in doses of 20 mg or 30 mg through intravenous administration, following the approved drug label and routine clinical practice. This is an observational study, meaning the treatment is given as part of standard care, and the researchers gather data without changing the treatment. The observation period lasts up to 48 weeks after the first dose. If treatment stops earlier, participants are followed for 30 days after the last dose or until they start a different cancer medicine. During the study, medical records will be reviewed regularly to monitor any adverse events, including serious or unexpected reactions, and to track the status of the cancer. Researchers will also check overall survival and progression-free survival up to 48 weeks. Participants' health will be observed for about one year, with data collection focusing on safety and treatment effects in real-world clinical settings.

A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection